ClinicalTrials.gg
CompletedNCT00200200Updated Oct 30, 2026Results posted

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

A Phase 2 interventional study of Bevacizumab HAI plus systemic chemotherapy and HAI plus systemic chemotherapy in Hepatic Metastases, Colon Cancer and Rectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 5 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 9 under way, none of them phase 3. Colonic Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
6th of 24
73 · median 37
Started
2004
with 2 others
Phase 2
15 of 53
1 open now
Registered
25th of 53
by date

Among the 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2004, is one of 15 in phase 2, and was the 25th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

4 of the 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will increase disease free survival in patients who have undergone liver resection. The patient will be randomized (a computer generated decision as in the flip of a coin) to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy.

03

Conditions studied

  • Hepatic Metastases
  • Colon Cancer
  • Rectal Cancer

Keywords

  • BEVACIZUMAB (AVASTIN)
  • DEXAMETHASONE
  • FLOXURIDINE
  • FLUOROURACIL
  • IRINOTECAN (CPT-11) CAMPTOSAR
  • LEUCOVORIN
  • OXALIPLATIN
  • Colon
  • Rectal
  • 04-086
  • Adjuvant postoperative chemo for CLM
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of confirmed colorectal adenocarcinoma to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC.
  • Potentially completely resectable hepatic metastases without current evidence of other metastatic disease.
  • Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to registration. (MRI of abdomen may be substituted for CT of abdomen.)
  • Lab values within 14 days prior to registration:

    • WBC ≥ 3.0 K/uL
    • > 1.5 K/uL
    • ≥ 75 K/uL
    • Total \< 1.5 mg/dL
    • \< 1.5
    • Creatinine \< 2.0 mg/dL
    • HGB ≥ 9 gm/dL
  • Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. [Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.]
  • ≥ 70%
  • Signed
  • Patient age must be >18

Exclusion criteria

Exclusion Criteria:

  • Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.)
  • Active infection, ascites, hepatic encephalopathy.
  • Prior treatment with HAI FUDR.
  • Female patients who are pregnant or lactating.
  • Subjects discovered to have ≥1+ proteinuria at baseline will undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \<1 g of protein/24 hours to allow participation in this study.
  • Patients may not be receiving any other agents
  • Patients with known that would confound the evaluation of neurologic and other adverse events will be excluded. Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab.
  • Serious or non-healing active wound, ulcer, or bone fracture
  • Major surgical procedure, open or significant traumatic injury within 28 days prior to Day 1 of protocol treatment. (Surgery performed to resect lesions and place pump will not exclude patient from protocol; Day 1 of protocol treatment will take place no sooner than 28 days after surgery.)
  • Current or recent use of a thrombolytic agent.
  • Chronic daily treatment with aspirin (> 325 mg/d) or nonsteroidal anti-inflammatory medications known to inhibit the function.
  • Presence of bleeding diathesis or coagulopathy.
  • History of serious systemic disease, including myocardial infarction within the last 12 months, uncontrolled hypertension (blood pressure of > 160/110 mmHg on medication), unstable angina within the last 12 months, (NYHA) Grade II or greater congestive heart failure (see Appendix C), unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i. e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater).
  • Patients with a history of stroke or .
  • Presence of central nervous system or brain metastases.
  • Patients who have a diagnosis of Gilbert's disease.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Active comparator
    1

    Bevacizumab in addition to HAI plus systemic chemotherapy

    Drug: Bevacizumab HAI plus systemic chemotherapy

  • Experimental
    2

    HAI plus systemic chemotherapy alone

    Drug: HAI plus systemic chemotherapy

Interventions

  • DrugBevacizumab HAI plus systemic chemotherapy

    Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours

  • DrugHAI plus systemic chemotherapy

    Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes

06

What researchers measure

Primary outcomes

  1. Relapse Free Survival/RFS

    To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer

    Time frame: 1 year

Secondary outcomes

  1. Number of Participants Assessed for Toxicity

    To assess toxicity

    Time frame: 7.5 months

  2. To Determine Survival

    Time frame: 2 years

Other outcomes

  1. To Compare Plasma Levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ Circulating Endothelial Progenitors

    Time frame: 2 years

  2. To Assess the Expression Pattern of VEGFR1, VEGFR2 (Angiogenesis), and VEGFR3 (Lymphangiogenesis) and Their Cognate Ligands (VEGF-A, VEGF-C, VEGF-D), and Correlate With Patient Progression and Survival Following

    Time frame: 2 years

07

Results

Posted Oct 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
Started3538
Completed2430
Not completed118
Withdrew: Adverse event64
Withdrew: Physician decision33
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryRelapse Free Survival/RFS

To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer

Time frame:
1 year
Reported as:
Number · percentage of participants at 1 year
Relapse Free Survival/RFS
percentage of participants at 1 yearBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
Relapse Free Survival/RFS71 (52 to 83)83 (66 to 92)
SecondaryNumber of Participants Assessed for Toxicity

To assess toxicity

Time frame:
7.5 months
Reported as:
Count of participants · Participants
Number of Participants Assessed for Toxicity
ParticipantsBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
Number of Participants Assessed for Toxicity3538
SecondaryTo Determine Survival
Time frame:
2 years
Reported as:
Count of participants · Participants
To Determine Survival
ParticipantsBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
Alive1720
Dead1818
Other pre-specifiedTo Compare Plasma Levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ Circulating Endothelial Progenitors
Time frame:
2 years

No measurements were reported for this outcome.

Other pre-specifiedTo Assess the Expression Pattern of VEGFR1, VEGFR2 (Angiogenesis), and VEGFR3 (Lymphangiogenesis) and Their Cognate Ligands (VEGF-A, VEGF-C, VEGF-D), and Correlate With Patient Progression and Survival Following
Time frame:
2 years

No measurements were reported for this outcome.

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab in Addition to HAI Plus Systemic Chemotherapy18/35 (51.4%)16/35 (45.7%)30/35 (85.7%)
HAI Plus Systemic Chemotherapy Alone18/38 (47.4%)10/38 (26.3%)9/38 (23.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
DiarrheaGastrointestinal disorders4/354/38
Pain - Abdomen NOSGastrointestinal disorders1/354/38
Liver dysfunction/failureHepatobiliary disorders2/350/38
Thrombosis/thrombus/embolismVascular disorders2/350/38
Febrile neutropeniaBlood and lymphatic system disorders0/352/38
Bilirubin (hyperbilirubinemia)Investigations1/350/38
Hemorrhage/Bleeding, otherInjury, poisoning and procedural complications1/350/38
Infection w/ Gr 3/4 neut, Anal/perianalInfections and infestations1/350/38
Infection, otherInfections and infestations1/350/38
Musculoskeletal/Soft Tissue - OtherMusculoskeletal and connective tissue disorders1/350/38
Most frequent other events
Most frequent other events
EventBevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy Alone
Alkaline phosphatase two fold or higher increaseInvestigations11/356/38
DiarrheaGastrointestinal disorders6/353/38
Bilirubin > 3mg/dLInvestigations5/350/38
Biliary stentsHepatobiliary disorders4/350/38
ThrombosisVascular disorders3/350/38
Abdominal PainGastrointestinal disorders1/353/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy AloneTotal
Mean53 (35 to 74)54 (29 to 77)53.5 (29 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy AloneTotal
Female191635
Male162238
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy AloneTotal
Hispanic or Latino022
Not Hispanic or Latino000
Unknown or Not Reported353671
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy AloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White353570
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Bevacizumab in Addition to HAI Plus Systemic ChemotherapyHAI Plus Systemic Chemotherapy AloneTotal
United States353873
08

Study locations

5 sites
  • Memorial Sloan Kettering Basking Ridge (Follow Up Only)
    Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Cancer Commack (Follow Up Only)
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester (Follow Up Only)
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau (Follow Up Only)
    Uniondale, New York 11553, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Mar 2025 and a completion of Mar 2025. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
Nov 19, 2004
Primary completionActual
Mar 13, 2025
CompletionActual
Mar 13, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancerNow Relapse Free Survival/RFSTime frame: 7.5 months → 1 year
Oct 30, 2026
Documents
Secondary outcomes
1 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedTo determine survivalDetermine SurvivalTime frame: 2 years
  • AddedNumber of Participants Assessed for ToxicityTime frame: 7.5 months
  • RemovedTo assess toxicityTime frame: 7.5 months
  • RemovedTo assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival followingTime frame: 2 years
  • RemovedTo compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitorsTime frame: 2 years
  • Addedother outcomeTo Compare Plasma Levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ Circulating Endothelial ProgenitorsTime frame: 2 years
  • Addedother outcomeTo Assess the Expression Pattern of VEGFR1, VEGFR2 (Angiogenesis), and VEGFR3 (Lymphangiogenesis) and Their Cognate Ligands (VEGF-A, VEGF-C, VEGF-D), and Correlate With Patient Progression and Survival FollowingTime frame: 2 years
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancerNow Relapse Free Survival/RFSTime frame: 7.5 months → 1 year
    Secondary outcomes 1 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedTo determine survivalDetermine SurvivalTime frame: 2 years
    • AddedNumber of Participants Assessed for ToxicityTime frame: 7.5 months
    • RemovedTo assess toxicityTime frame: 7.5 months
    • RemovedTo assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival followingTime frame: 2 years
    • RemovedTo compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitorsTime frame: 2 years
    • Addedother outcomeTo Compare Plasma Levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ Circulating Endothelial ProgenitorsTime frame: 2 years
    • Addedother outcomeTo Assess the Expression Pattern of VEGFR1, VEGFR2 (Angiogenesis), and VEGFR3 (Lymphangiogenesis) and Their Cognate Ligands (VEGF-A, VEGF-C, VEGF-D), and Correlate With Patient Progression and Survival FollowingTime frame: 2 years
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00200200
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Nov 19, 2004
Primary completion
Mar 13, 2025
Completion
Mar 13, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Nancy Kemeny, M.D
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion